Intrahepatic cholestasis of pregnancy: Introduction and overview 2024
- PMID: 39262909
- PMCID: PMC11384812
- DOI: 10.1177/1753495X241265772
Intrahepatic cholestasis of pregnancy: Introduction and overview 2024
Abstract
Considerable progress has been made to explain the aetiology of intrahepatic cholestasis of pregnancy (ICP) and of the adverse pregnancy outcomes associated with high maternal total serum bile acids (TSBAs). The reported thresholds for non-fasting TSBA associated with the risk of stillbirth and spontaneous preterm birth can be used to identify pregnancies at risk of these adverse outcomes to decide on appropriate interventions and to give reassurance to women with lower concentrations of TSBA. Data also support the use of ursodeoxycholic acid to protect against the risk of spontaneous preterm birth. A previous history of ICP may be associated with higher rates of subsequent hepatobiliary disease: if there is a suspicion of underlying susceptibility, clinicians caring for women with ICP should screen for associated disorders or for genetic susceptibility and, where appropriate, refer for ongoing hepatology review.
Keywords: Intrahepatic cholestasis of pregnancy; diagnosis; pregnancy complications; pruritus; treatment.
© The Author(s) 2024.
Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
References
-
- Eloranta ML, Eloranta M-L, Heinonen S, et al. Risk of obstetric cholestasis in sisters of index patients. Clin Genet 2001; 60: 42–45. - PubMed
-
- Reyes H, Báez ME, González MC, et al. Selenium, zinc and copper plasma levels in intrahepatic cholestasis of pregnancy, in normal pregnancies and in healthy individuals, in Chile. J Hepatol 2000; 32: 542–549. - PubMed
LinkOut - more resources
Full Text Sources